HIGHLIGHTS
- who: Kazuhiko Nakagawa from the Eli Lilly and Company, Bridgewater, USA have published the research work: RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship, in the Journal: (JOURNAL)
- what: Detailed methods of this trial have been reported previously . Though no preclinical study was conducted to demonstrate Cmin was the driver for efficacy, preclinical data showed tumor shrinkage was observed in a mice xenograft model with steady_state Cmin ramucirumab concentration greater than a threshold limit of approximately 20 ug/mL . Ordered categorical models . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.